N-(indan-5-yl)-2-thioxo-1,2-dihydropyridine-3-carboxamide | 864461-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(indan-5-yl)-2-thioxo-1,2-dihydropyridine-3-carboxamide
• 英文别名: N-(2,3-dihydro-1H-inden-5-yl)-2-sulfanylidene-1H-pyridine-3-carboxamide
• CAS: 864461-01-8
• 化学式: C₁₅H₁₄N₂OS
• 分子量: 270.355
• InChiKey: MYGILEDMSPDFDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
  申请人：Honda Takahiro

  公开号：US20070149574A1

  公开（公告）日：2007-06-28

  A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R 1 and R 2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R 3 and R 4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R 5 , etc.; R 5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR 6 —, —SO 2 —, etc.; R 6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.

  一种具有4-吡啶基烷基硫基团的新型环状化合物，其中引入了（未）取代氨基或其盐。它们可用作药物。环状化合物是由以下式（1）表示的化合物，可用于治疗参与血管生成的疾病。在下式（1）中，环A表示苯环或5-或6-成员芳香杂环，可选择地与环烷环融合；B表示烷基；R1和R2各表示H，（取代）芳基，（取代）杂环基等；R3和R4各表示H，（取代）烷基，（取代）环烷基，-Z-R5等；R5表示（取代）烷基，（取代）芳基，（取代）杂环基等；X和Y各表示H等；Z表示-CO-，-COO-，-CONR6-，-SO2-等；R6表示H等；p为0、1或2；q为0或1。
• Novel Cyclic Compound Having Pyrimidinylalkylthio Group
  申请人：Tajima Hisashi

  公开号：US20090291951A1

  公开（公告）日：2009-11-26

  The present invention has its object to study synthesis of novel cyclic compounds having a pyrimidinylalkylthio group and to find pharmacological actions of the compounds. According to the present invention, a compound represented by the formula (1) or a salt thereof is provided. In the formula, the ring X represents: R 1 and R 2 independently represent a hydrogen atom, an alkyl group, an aryl group, an aromatic heterocyclic group or the like; R 3 represents a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an aryloxy group, an alkyl group, an aryl group, an amino group, an alkylamino group or the like; A 1 represents a sulfur atom or the like; and A 2 represents an alkylene group.

  本发明旨在研究具有嘧啶基烷基硫基团的新型环状化合物的合成，并找到这些化合物的药理作用。根据本发明，提供了由式（1）表示的化合物或其盐。其中，环X表示：R1和R2独立地表示氢原子、烷基、芳基、芳香杂环基或类似物；R3表示氢原子、卤原子、羟基、烷氧基、芳氧基、烷基、芳基、氨基、烷基氨基或类似物；A1表示硫原子或类似物；A2表示烷基链。
• Novel cyclic compound having pyrimidinylalkylthio group
  申请人：Tajima Hisashi

  公开号：US20110124646A1

  公开（公告）日：2011-05-26

  A method of treating a disease associated with angiogenesis by administering a therapeutically effective amount of a compound represented by the formula (1) or a salt thereof wherein the ring X represents R 1 and R 2 independently represent a hydrogen atom, an alkyl, an aryl or an aromatic heterocyclic; R 3 represents a hydrogen atom, a halogen atom, a hydroxy, an alkoxy, an aryloxy, an alkyl, an aryl, an amino, an alkylamino, a cycloalkylamino, an arylamino, an alkylcarbonylamino, an arylcarbonylamino, a mercapto, an alkylthio, an arylthio, an alkylsulfinyl or a nonaromatic heterocyclic; A 1 represents a sulfur atom, a sulfinyl or a sulfonyl; and A 2 represents an alkylene.

  通过给予化合物公式（1）或其盐的治疗有效量，治疗与血管生成相关的疾病的方法，其中环X代表R1和R2分别代表氢原子，烷基，芳基或芳香族杂环；R3代表氢原子，卤原子，羟基，烷氧基，芳氧基，烷基，芳基，氨基，烷基氨基，环烷基氨基，芳基氨基，烷基羰基氨基，芳基羰基氨基，巯基，烷硫基，芳硫基，烷基亚磺酰基或非芳香族杂环；A1代表硫原子，亚磺酰基或磺酰基；A2代表烷基。
• NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1717229B1

  公开（公告）日：2011-06-15
• NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1864977B1

  公开（公告）日：2015-07-29